Drug Interactions

lmidafenacin is primarily metabolized by CYP3A4 and UGT1A4 in the liver. lmidafenacin (Uritos®) should be administered with care when co-administered with the following drugs.

Drugs Signs, Symptoms, and Treatment Mechanism and Risk Factors
Drug Inhibiting CYP3A4:    Itraconazole    erythromycin clarithromycin , etc. When this product was co-administered with itraconazole to healthy adult males, Cmax and AUC of the product increased to about 1.3 and 1.8 times those of monotherapy, respectively. Since this product is primarily metabolized by CYP3A4, metabolism of this product is inhibited by these drugs.
Anticholinergic agents Antihistaminic agents , Tricyclic antidepressants Phenothiazines Monoamine oxidase   inhibitors Symptoms including thirst/dry mouth, constipation, and dysuria may occur potently. The anticholinergic effect of this product may be enhanced by these drugs.